Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...
Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer Patients with MCRC were randomly ...
High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...
Please provide your email address to receive an email when new articles are posted on . Researchers observed reduced risk for disease progression and death with the investigative combination.
ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...
FDA APPROVES GENENTECH’S AVASTIN (BEVACIZUMAB) PLUS CHEMOTHERAPY AS A TREATMENT FOR WOMEN WITH ADVANCED OVARIAN CANCER FOLLOWING INITIAL SURGERY – Avastin is now approved for ten distinct uses across ...
A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line chemotherapy for patients with ovarian cancer, ...
Bevacizumab, a humanised monoclonal antibody targeting vascular endothelial growth factor (VEGF), has become integral to the management of metastatic colorectal cancer (mCRC). By binding VEGF and ...
Roche Holding AG's Avastin may increase a cancer patient's risk of having a fatal reaction to treatment when it is added to chemotherapy, researchers said. Deadly side effects occurred in 2.5 percent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results